News

An epidemic of chronic diseases continues to grow in the United States; half the population — an estimated 129 million Americans — have lifelong health conditions that need continuous medical attention and limit certain daily activities.

Every day for the next five years, 10,000 Baby Boomers will turn 65, and by 2030, 18 percent of the U.S. population will be age 65 or older according to the Pew Research Center. While old age certainly doesn’t begin at 65, it’s not unreasonable to think as we age, we may need help from loved ones. Millions of Americans already act as caregivers each year.

For neurologists working with patients with Alzheimer’s disease, the road to actual treatment options has been long and paved with setbacks.

But that is changing for some patients. The Food and Drug Administration recently granted full approval to Leqembi® (lecanemab), the first disease-modifying treatment fully approved for patients in the early stages of Alzheimer’s disease. The development of this new drug offers hope to patients and may have lasting impacts on how physicians approach treatment.